Dana-Farber researchers present major cancer clinical trial results, including AI-driven data analysis, at ESMO Congress 2025.
Key Details
- 1Dana-Farber leads four phase 3 studies in breast, lung, and bladder cancer at ESMO Congress 2025.
- 2Key trials address advanced breast cancer treatment, NSCLC first-line therapy, and ctDNA-guided therapy in bladder cancer.
- 3Patient-reported data from SERENA-6 trial shows improved quality of life for metastatic breast cancer patients.
- 4Presentation of AI-generated synthetic cohorts from a 19,164 patient metastatic breast cancer dataset for real-world data analysis.
- 5Blood biomarker (KIM-1) study may help guide advanced kidney cancer treatment decisions.
- 6ESMO 2025 held in Berlin, Oct 17–21, with global participation.
Why It Matters
The use of AI to generate synthetic cohorts and analyze real-world oncology data can accelerate clinical trials and protect patient privacy, representing significant advancements for radiology, cancer informatics, and AI communities. These developments offer pathways to improved research collaboration and personalized cancer care.
Source
EurekAlert
Related News
•EurekAlert
New VIS-Fb Nanobody Probes Transform High-Precision Cellular Imaging
Salk and Einstein researchers have developed visible-spectrum antigen-stabilizable fluorescent nanobodies (VIS-Fbs) for sharper, multi-color live-cell imaging with minimal background noise.
•EurekAlert
NIH-Backed AI Model Predicts Cancer Survival Using Single-Cell Data
Researchers have developed scSurvival, a machine learning tool that uses single-cell tumor data to accurately predict cancer patient survival and identify high-risk cell populations.
•EurekAlert
Deep Learning Pathomics Platform Improves Immunotherapy Prediction in Lung Cancer
A deep learning pathomics platform accurately predicts immunotherapy response in metastatic NSCLC using routine pathology slides.